MAPT and periodontal disorder: Furthermore, in the current studies, a diverse set of experiments indicated that GV1001 administration appears to suppress neuroinflammation, inhibit the penetration of Pg into the brain, alleviate the accumulation of Pg LPS and gingipain aggregates, and reduce the levels of Aβ42 and p-Tau in the brains of mice with Pg-induced periodontal disease.